Changes in lipid metabolism driven by steroid signalling modulate proteostasis in C. elegans
EMBO reports · 2023
DOI: 10.15252/embr.202255556 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO reports, 2023. Verfasst von Ana P Gómez-Escribano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Caenorhabditis elegans Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIH HHS, Federal Railroad Administration.
Abstract (Originalsprache)
Alzheimer's, Parkinson's and Huntington's diseases can be caused by mutations that enhance protein aggregation, but we still do not know enough about the molecular players of these pathways to develop treatments for these devastating diseases. Here, we screen for mutations that might enhance aggregation in Caenorhabditis elegans , to investigate the mechanisms that protect against dysregulated homeostasis. We report that the stomatin homologue UNC‐1 activates neurohormonal signalling from the sulfotransferase SSU‐1 in ASJ sensory/endocrine neurons. A putative hormone, produced in ASJ, targets the nuclear receptor NHR‐1, which acts cell autonomously in the muscles to modulate polyglutamine repeat (polyQ) aggregation. A second nuclear receptor, DAF‐12, functions oppositely to NHR‐1 to maintain protein homeostasis. Transcriptomics analyses of unc‐1 mutants revealed changes in the expression of genes involved in fat metabolism, suggesting that fat metabolism changes, controlled by neurohormonal signalling, contribute to protein homeostasis. Furthermore, the enzymes involved in the identified signalling pathway are potential targets for treating neurodegenerative diseases caused by disrupted protein homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
- Joint Unit for Rare Diseases IIS La Fe-CIPF, Valencia, Spain.
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
- Unidad Analítica, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
- Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.
ORCID-Profile: Ana P Gómez-Escribano, Carlos Mora-Martínez, Marta Roca, Denise S Walker, Maria D Sequedo, Hans-Joachim Knölker, José M Millán, William R Schafer, Rafael P Vázquez-Manrique
Förderung
- Medical Research Council
- NIH HHS
- Federal Railroad Administration
Zitieren
APA
Gómez-Escribano, A. P., Mora-Martínez, C., Roca, M., Walker, D. S., Panadero, J., Sequedo, M. D., Saini, R., Knölker, H. J., Blanca, J., Burguera, J., Lahoz, A., Cañizares, J., Millán, J. M., Burton, N. O., Schafer, W. R., & Vázquez-Manrique, R. P. (2023). Changes in lipid metabolism driven by steroid signalling modulate proteostasis in C. elegans. EMBO reports. https://doi.org/10.15252/embr.202255556
Vancouver
Gómez-Escribano AP, Mora-Martínez C, Roca M, Walker DS, Panadero J, Sequedo MD, et al. Changes in lipid metabolism driven by steroid signalling modulate proteostasis in C. elegans. EMBO reports. 2023. doi:10.15252/embr.202255556
BibTeX
@article{GmezEscribano2023,
author = {Gómez-Escribano, Ana P and Mora-Martínez, Carlos and Roca, Marta and Walker, Denise S and Panadero, Joaquín and Sequedo, Maria D and Saini, Ratni and Knölker, Hans-Joachim and Blanca, Jose and Burguera, Juan and Lahoz, Agustin and Cañizares, Joaquin and Millán, José M and Burton, Nick O and Schafer, William R and Vázquez-Manrique, Rafael P},
title = {Changes in lipid metabolism driven by steroid signalling modulate proteostasis in C. elegans},
journal = {EMBO reports},
year = {2023},
doi = {10.15252/embr.202255556}
}
EUVIMED